Stance Capital LLC Grows Position in Eli Lilly and Company $LLY

Key Points

• Stance Capital LLC increased its stake in Eli Lilly and Company by 367.3% in the first quarter, now owning 1,514 shares valued at approximately $1.25 million.
• Institutional investors hold 82.53% of Eli Lilly's stock, with notable changes including PNC Financial's share increase of 97.5% and GAMMA Investing's astonishing upsurge of 103,831.6%.
• Eli Lilly reported a 37.6% year-over-year revenue increase, reaching $15.56 billion, and exceeded the consensus earnings estimate by $0.72 with an EPS of $6.31.

Stance Capital LLC increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 367.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,514 shares of the company's stock after purchasing an additional 1,190 shares during the quarter. Stance Capital LLC's holdings in Eli Lilly and Company were worth $1,251,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. WestEnd Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $27,000. Citizens National Bank Trust Department lifted its holdings in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $40,000. Finally, Mascagni Wealth Management Inc. bought a new stake in Eli Lilly and Company in the 4th quarter worth $43,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 1.5%

Shares of LLY traded up $11.35 during trading on Tuesday, reaching $749.99. The company's stock had a trading volume of 2,983,536 shares, compared to its average volume of 4,436,129. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $942.35. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market cap of $709.84 billion, a price-to-earnings ratio of 49.02, a P/E/G ratio of 1.03 and a beta of 0.47. The company has a fifty day moving average of $743.02 and a two-hundred day moving average of $779.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the business posted $3.92 earnings per share. The company's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is currently 39.22%.

Insider Transactions at Eli Lilly and Company

In related news, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gabrielle Sulzberger bought 117 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company's stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.14% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent analyst reports. HSBC raised shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their target price for the stock from $675.00 to $700.00 in a report on Wednesday, August 27th. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Guggenheim decreased their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.